Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Iovance Biotherapeutics Inc(IOVA)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IOVA
09/25/2026: IOVA (4-star) is a STRONG-BUY. BUY for 51 days. Simulated Profits (136.05%). Updated daily EoD!
Iovance Biotherapeutics is an innovative biotechnology firm that has achieved a milestone with the FDA approval of Amtagvi, its TIL cell therapy for solid tumors. The company's main strength is its proprietary platform that empowers the immune system to combat cancer, effectively creating a first-mover advantage in this space. Its primary growth opportunity lies in expanding the use of its therapy to a broader range of cancer types. However, the company faces significant execution and competition risks, given the complex logistics of its patient-specific treatments and the substantial resources of oncology giants. It is suited for growth-oriented investors who are comfortable with the inherent volatility of the biotech sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company provides pure-play exposure to the nascent and high-potential TIL cell therapy segment. |
| Momentum investor | Mixed fit | Momentum depends heavily on positive news flow regarding commercial adoption and future clinical readouts. |
| Value investor | Weak fit | As a pre-profit, R&D-intensive biotech, it does not meet traditional value metrics. |
| Dividend investor | Weak fit | The company is in a growth phase and does not pay dividends. |
| Low-risk investor | Weak fit | The biotech sector and early-stage commercial rollouts carry high volatility and execution risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are sensitive to clinical trial outcomes and regulatory news. |
| Valuation risk | High | Valuations are often speculative, based on long-term growth expectations rather than current earnings. |
| Competition risk (oncology) | Medium / high | Established players have massive resources to challenge Iovance's market position. |
| Business quality | Medium | The business is at a critical transition from clinical research to commercial manufacturing. |
| Dividend income | Low / none | No dividends are expected as capital is prioritized for clinical development. |
| Execution risk | High | Scaling complex patient-specific therapies requires flawless logistics and clinical site adoption. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 132.31% | Avg. Invested days 22 | Today’s Advisory Regular Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.89B USD | Price to earnings Ratio - | 1Y Target Price 10.7 |
Price to earnings Ratio - | 1Y Target Price 10.7 | ||
Volume (30-day avg) 15.3M shares | Beta 0.83 | 52 Weeks Range 1.76 - 11.13 | Updated Date 09/25/2026 |
52 Weeks Range 1.76 - 11.13 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Sales of Amtagvi (lifileucel) and potential future approved therapies. | Revenue comes from selling high-cost, personalized cancer treatments to hospital systems. |
| Geography | Primarily US market operations currently. | The company's commercial success is currently tied to US-based oncology centers. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4.55B | Price to Sales(TTM) 15.05 |
Enterprise Value 4.55B | Price to Sales(TTM) 15.05 | ||
Enterprise Value to Revenue 14 | Enterprise Value to EBITDA -8.68 | Shares Outstanding 452.97M | Shares Floating 394.31M |
Shares Outstanding 452.97M | Shares Floating 394.31M | ||
Percent Insiders 0.35 | Percent Institutions 70.67 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Iovance Biotherapeutics Inc
Exchange NASDAQ | Headquarters San Carlos, CA, United States | ||
IPO Launch date 2010-10-15 | Interim CEO, President, General Counsel, Corporate Secretary & Director Dr. Frederick G. Vogt Esq., J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 975 | Website https://www.iovance.com |
Full time employees 975 | Website https://www.iovance.com | ||
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.